Request Demo
Request Demo

Counterfeit Medicine Roundup: June and July 2026

Two months, four continents, and one theme that kept repeating: the fake product looked right.

That is the thread running through almost everything that happened across June and July. A tablet with a convincing imprint. A vial with a real batch number. A pen with the correct label. A website that looks like a pharmacy. In case after case, the only thing standing between a patient and a counterfeit was a visual judgement that nobody was equipped to make.

Here is what happened, and what it says about where the threat is going.

Europe put a number on the fake-pill problem

On 9 June, the European Union Drugs Agency published its European Drug Report 2026, and buried in it was one of the more alarming trend lines of the year. Counterfeit tablets containing nitazenes, a class of synthetic opioids that can be far more potent than heroin, are spreading fast. Ten European countries seized more than 50,000 nitazene-containing tablets in 2024. In 2023 the figure was 23,000. In 2022 it was 380.

The tablets are made to resemble prescription medicines, most often oxycodone, and to a lesser extent benzodiazepines such as diazepam and alprazolam. The agency’s own framing is the important part: the authentic appearance of these products creates a false sense of security. People taking them may have no idea they are consuming a synthetic opioid at all, and the EUDA warned that the tablets may spread to groups with no opioid tolerance, including young people.

The report landed alongside Europol’s Operation SHIELD VI enforcement results and a joint EUDA, Europol and European Medicines Agency public awareness campaign, “Stay on Top – EU vs Fake Medicines,” urging consumers to buy only from authorised sources.

That is the right message. It is also an incomplete one, because “buy from authorised sources” does not help when the counterfeit is already sitting inside a legitimate supply chain, which is exactly what happened repeatedly over these two months.

Retatrutide became the defining counterfeit story of the summer

If one product dominated the news cycle across June and July, it was a drug that does not legally exist yet.

Retatrutide is an experimental weight-loss compound still in clinical trials, not approved by any regulator anywhere in the world. It has nevertheless become one of the most widely trafficked pharmaceutical products on the internet, and the harm reports piled up quickly.

In the United Kingdom, MHRA records reported by the Daily Mail showed a man died in 2025 after taking retatrutide, with reported side effects up roughly 350 percent in 2026 compared with all of 2025, including eight suspected liver, gallbladder, pancreas and bile duct complications. One patient with acute liver failure was considered for a transplant before being stabilised.

Australian health officials issued warnings in late June after multiple cases of severe illness linked to products sold as retatrutide, including acute liver failure, kidney injury and hospitalisations, sourced through social media, beauty clinics and online sellers. Australia’s Therapeutic Goods Administration launched a wider crackdown on unapproved peptides on 10 June. New Zealand’s Medsafe followed with its own consumer advisory. Malta warned the public in mid-June. In the Netherlands, hospitals reported two people falling into comas after taking counterfeit weight-loss drugs bought online that contained only insulin. Denmark reported a sharp increase in poisonings from counterfeit weight-loss products.

In the United States, CBS News found more than 120 websites and dozens of clinics and med spas openly advertising or prescribing the drug, and reported that exposures to America’s Poison Centers had climbed to an average of 95 cases a month in early 2026, a 265 percent increase over late 2025. In July, CBS reporters bought a vial labelled as retatrutide from a New York City bodega for 95 dollars, with no age verification, no questionnaire and no prescription. The Partnership for Safe Medicines found that roughly 15 pounds of retatrutide entered the US between January and April 2026.

Two data points frame why any of this matters for authentication. First, a study of self-reported side effects among Reddit users found symptom patterns that diverged sharply from Eli Lilly’s clinical trial data, a discrepancy the researchers noted may simply mean that much of what is sold as retatrutide is not retatrutide. Second, an analysis of consumer-submitted samples from a peptide testing facility found that 71 percent of grey-market samples failed to meet FDA manufacturing standards, 15 percent contained measurable bacterial endotoxins, and 2 percent did not contain the peptide on the label at all.

Blockchain analytics firm Chainalysis put the crypto-powered grey-market peptide trade at more than 100 million dollars a year, and linked some overseas suppliers to Chinese chemical manufacturers that previously sold fentanyl and amphetamine precursors. Those firms did not exit the criminal economy. They changed product lines.

Cancer drugs kept turning up

On 4 June, sources confirmed to the International Consortium of Investigative Journalists that Mexican federal authorities had seized vials labelled as Keytruda during an operation to dismantle a counterfeit ring outside Mexico City. It was the second such operation involving vials bearing Keytruda labels. The same joint action recovered 15,000 doses of clonazepam, more than 100 counterfeit vaccines and 1,000 vaccine labels.

In early July, the World Health Organization issued a warning after batches of counterfeit Darzalex, a bone marrow cancer treatment, were found in the Maldives. Myanmar’s regulator warned of counterfeit Albutein 20% Solution circulating in the country, identifiable in part by an incorrect “IP Specification” label and a missing national registration number. Kenyan authorities warned about a counterfeit batch of the breast cancer drug Phesgo, distinguishable because the fake contained a white powder rather than the ready-to-use liquid of the genuine product.

The pattern is consistent with what ICIJ’s earlier Cancer Calculus investigation described: high-priced oncology medicines create a price gap, the price gap creates demand for cheaper supply, and criminal networks fill it using authentic batch numbers and refilled vials. When the fake carries a real lot number, serialisation alone does not resolve the question.

India ran a near-continuous enforcement campaign

Indian authorities logged counterfeit medicine actions at a rate of several per week through July.

In Puducherry, a sting operation shut down a facility producing fake Pregabalin-150 tablets as part of an international network, with 300,000 counterfeit tablets and packaging materials seized and the owner arrested. Haryana’s FDA busted a racket supplying spurious Telma-AM, a widely prescribed blood pressure combination, arresting two on 20 July; a follow-up joint raid with Delhi authorities two days later recovered a further 560 fake blister packs and uncovered an unlicensed warehouse.

Uttarakhand’s Special Task Force raided a factory in Bazpur producing spurious allopathic medicines without a licence, seizing packaging machinery and excise holograms alongside the drugs. A separate raid in Dehradun on 23 July uncovered another counterfeit manufacturing unit stocked with fake versions of leading pharma brands and their packaging material. Uttar Pradesh’s FSDA exposed an interstate network in Meerut and Baghpat that was packaging food supplements as the life-saving drug Evion 400.

Late July brought more: a fake drug and anabolic steroid manufacturing setup inside a residential apartment in Delhi’s Narela, uncovered in a two-day joint operation involving Haryana FDA and Delhi Police, and a large cache of suspected counterfeits seized in Gaya, Bihar. In Gurgaon, a court denied bail to the accused ringleader of a counterfeit Mounjaro operation dismantled in April.

The recurring detail worth noting is the packaging machinery. These are not crude operations. They are production lines with the equipment to make convincing artwork, and the holograms seized in Uttarakhand make the point better than any statistic: the security feature was manufactured on site.

Nigeria escalated on every front at once

Nigeria had one of the busiest months of any single country.

On 15 July, the Nigeria Customs Service announced the interception at Apapa Port of fake NAFDAC-labelled medicines, illicit drugs and expired pharmaceutical products with a combined duty paid value of ₦53.39 billion. The consignment initially appeared legitimate; the giveaway was a NAFDAC certificate that verification showed to be fraudulent. The same day, traders at the Bridge Head Drug Market in Onitsha handed over 192 consignments of substandard, falsified and expired medicines worth ₦435 million to NAFDAC for destruction, recovered through surveillance in the market between December 2025 and June.

NAFDAC issued Public Alert 036/2026 on 21 July over suspected counterfeits mimicking AstraZeneca’s Forxiga (dapagliflozin), detected in eastern Nigeria under the near-identical names “Forzigar” and “Foziga” and imitating the AstraZeneca logo. In June, Enugu State’s health ministry warned that counterfeit Augmentin 625mg tablets were circulating, closely resembling the genuine GSK product and carrying the same batch number, AC3N.

On the legislative side, the Senate advanced the Counterfeit Medical Products, Fake Drugs and Unwholesome Processed Foods (Prohibition and Control) Bill 2026, which proposes 15-year jail terms, asset forfeiture, victim compensation and expanded NAFDAC enforcement powers, explicitly citing online drug sales, cross-border trafficking and increasingly sophisticated counterfeiting methods as the reason the existing law needs replacing.

Elsewhere in the region, Liberia’s Medicines and Health Products Regulatory Authority seized counterfeit and substandard medicines worth around L$400,000 in Bong County and launched a five-year regulatory strengthening plan on 25 June.

Enforcement and sentencing in the United States

Four Massachusetts men were sentenced to between 12 and 18 years for running a counterfeit pill operation that used five industrial pill presses and pharmaceutical-mimicking imprint tooling to produce fakes of oxycodone, Adderall and Xanax containing fentanyl, methamphetamine or bromazolam. Prosecutors linked the scheme to more than a dozen deaths.

Two New York defendants were convicted for operating industrial-scale pill pressing machines and selling the output as prescription medication to victims in all 50 states. In New Jersey, further members of a nine-person trafficking organisation were sentenced for importing fentanyl analogues from China and pressing them into counterfeit prescription pills; five of the nine have now received a combined 685 months.

A forensic laboratory in north Louisiana warned in July that nearly one in three street tablets bearing legitimate-looking drug imprints tested as counterfeit, with fentanyl the most common substance found and blue M30 tablets the most commonly faked. Their deputy director of toxicology put it plainly: the stamps look authentic, so you probably cannot tell the difference.

Three bipartisan bills targeting pill press equipment advanced to full committee in Congress: the Fight Illicit Pill Presses Act, the PRESS Act, and the Stop Pills That Kill Act. And in early July, Alibaba and its payment subsidiary agreed to pay 600 million dollars to settle Department of Justice allegations that their platform facilitated sales of illicit medications, precursor chemicals and counterfeit pill-making equipment between 2016 and 2024.

Regulators reached for verification systems

Several governments responded structurally rather than case by case.

Pakistan’s federal cabinet approved a nationwide pharmaceutical track-and-trace system aimed at eliminating counterfeit and substandard medicines. Ukraine registered its National Organization for the Verification of Medicinal Products, a step toward a national verification system using 2D coding to authenticate packaging and align with European standards.

In the UK, the MHRA, Advertising Standards Authority and General Pharmaceutical Council issued a joint warning against advertising unlicensed weight-loss medicines or prescription-only GLP-1 products to the public. The MHRA strengthened safety warnings for botulinum toxin type A products following rare botulism cases, noting that unlicensed and counterfeit versions are especially dangerous. Four members of a criminal group that sold almost two million doses of unauthorised prescription medicines online were sentenced to nearly 15 years combined following MHRA’s Operation Lamborghini.

British experts also warned of an expected surge in counterfeit weight-loss pills now that Wegovy in tablet form has entered legitimate supply chains. Pills, they noted, are far easier for criminals to copy than injectables, and fakes made from chalk and paint can be nearly undetectable by eye. The UK regulator has seized more than 6,500 fake weight-loss products in the past three years. Counterfeiters have cloned legitimate UK pharmacy websites, and discounts on fake injections have been kept modest specifically to avoid arousing suspicion. The chair of Parliament’s health and social care committee said publicly that she has very little confidence the MHRA can protect the country against counterfeit drugs at current resourcing.

Tajikistan rounded out the international picture, dismantling an operation producing fake versions of paediatric and over-the-counter medicines including Nurofen and Paracetamol, seizing tens of thousands of bottles along with packaging materials and raw ingredients.

The through-line

Read across two months and the shape is unmistakable.

The products being faked now span the full range: opioid analgesics, blood pressure combinations, antibiotics, epilepsy drugs, oncology biologics, plasma proteins, children’s fever medicine, vitamin supplements and weight-loss injectables. The channels span the full range too: bodegas, social media, cloned pharmacy websites, wholesale consignments through major ports, and licensed hospitals in at least four countries.

And the defence, almost everywhere in these stories, was a person looking at a package and deciding whether it seemed right. A customs officer looking at a certificate. A pharmacist looking at a strip. A patient looking at a pen.

That defence failed in Kota, in Mexico City, in the Maldives, in Lagos, in Northampton, in Amsterdam. It failed not because the people involved were careless, but because the fakes were manufactured on real equipment with real batch numbers and near-perfect artwork. When the counterfeiter has the packaging machine and the hologram press, the security feature stops being a security feature. It becomes a set of instructions.

This is the case for a different model. Authentication cannot depend on what a person can notice, and it cannot depend on features that can be copied along with everything else. It has to work from properties the product already has: the artwork, the print quality, the colour, the typography, the geometry, the microscopic signature of how a genuine package was actually produced. AI can read those in seconds from an ordinary photograph, with no sticker, no code, no hardware and no change to the supply chain.

That is what non-additive authentication means, and it is why TrueMed exists. Every story above is a story about a moment when someone could not tell the real from the fake fast enough. Closing that gap is the entire job.

Want to see how AI-powered, non-additive authentication protects your products and your patients? Talk to the TrueMed team.

Sources

New partnership extends AI-powered counterfeit detection to medications used by tens of millions of patients annually, covering a combined market exceeding $5 billion

Helsinki 08JUN2026. TrueMed, the leader in AI-based pharmaceutical counterfeit detection, today announced a commercial partnership with one of the world’s ten largest pharmaceutical companies. The agreement brings TrueMed’s AI-powered authentication platform to three of the partner’s established antibiotic and anti-infective products, medicines already in wide circulation that are prescribed to an estimated 60 to 80 million patients globally each year.

The three drug franchises covered represent a combined global market value of more than $5 billion and are dispensed across primary care, pediatric, and hospital settings in over 100 countries. Because these products are already in the field across more than 100 countries, their packaging is actively being replicated by counterfeiters.

TrueMed’s core advantage is that no supply chain changes, new serialization codes, or product reformulation are required. The platform authenticates packaging against the original artwork files already on record, comparing them to what is reaching pharmacies and patients. For drugs that have been on the market for years, this means protection can be activated immediately, against a threat that has been growing just as long.

“When a top-10 global pharma company brings three of its most prescribed products to us for protection, it validates what we’ve built, and signals where the industry is heading. Patient safety starts now, with the product already on your shelves, not after months of manufacturing changes.”

Jyrki Berg – CEO, TrueMed

Counterfeit antibiotics represent one of the most dangerous segments of the $200 billion global counterfeit pharmaceutical market. The World Health Organization estimates that up to 10% of medicines in low- and middle-income countries are substandard or falsified, with antibiotics among the most frequently targeted drug classes. The consequences range from treatment failure and weakened antibiotic effectiveness to direct patient harm.

TrueMed starts with the source of truth: each product’s original artwork file. Every package in the field is measured against it, with discrepancies in typography, color, print registration, and layout flagged automatically. Deployment takes weeks, not months. Submissions are frictionless — photograph suspect packaging, submit via mobile app or secure web portal, and get results instantly. A confirmed counterfeit automatically opens a case record in TrueMed Case Management, where it is logged, tracked, routed to the right contacts, and ready to share with authorities.

With three of the world’s most prescribed anti-infective products now under TrueMed protection, patients and providers can trust that the medicine in hand is exactly what it claims to be.

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas
TrueMed
tuomas.kannas@truemedinc.com

 

Counterfeit Medicine Roundup: May 2026

May was not a quiet month. From a global enforcement haul announced at the start of the month to five maternal deaths linked to fake oxytocin at the end of it, the news cycle delivered a steady stream of counterfeit medicine stories. What stood out was not just the volume. It was the variety. Antibiotics, antimalarials, oxytocin, rabies vaccines, cancer and liver drugs, weight-loss injectables, and fentanyl-laced pills all surfaced in seizures and investigations across at least four continents.

Here is what happened, and what it tells us about where the threat is heading.

Global enforcement scaled up

The month opened with the figures from INTERPOL’s Operation Pangea XVIII, which 90 countries used to target the online sale of illicit and counterfeit medicines. The operation produced 6.42 million seized doses worth roughly 15.5 million US dollars, 269 arrests, and the dismantling of 66 criminal groups. Investigators also took down around 5,700 websites, social media pages, and bots used to market fakes online. The UK led all countries by volume seized, followed by Colombia and Australia. The most commonly seized categories tell their own story: erectile dysfunction drugs, sedatives, painkillers, antibiotics, and anti-smoking products.

Africa featured heavily. Authorities in Burkina Faso intercepted 384,000 antibiotic capsules. In Cote d’Ivoire, officers pulled a full tonne of counterfeit ibuprofen from a single vehicle. Cameroon seized thousands of bottles of suspected fake antimalarials and antibiotics.

Days later, Europol announced one of the bigger network takedowns of the year. A coordinated action on May 12 ran 138 searches across Bulgaria, Greece, Hungary, Poland, Romania, and Moldova, with at least nine arrests. The criminal organization had operated for nearly two decades and moved an estimated 240 million euros in illicit transactions, much of it built on fake supplements sold to people with diabetes, cancer, and psoriasis through manipulative ads and fake endorsements. Investigators seized assets worth 17.7 million euros, identified a central warehouse in Bulgaria holding more than 300 types of illegally produced supplements, and blocked 196 selling websites in Romania.

The pattern across both operations is hard to miss. The web is now the storefront, and the criminals running it are organized, durable, and patient.

The WHO put the problem on the record

On May 13, the World Health Organization released a new toolkit warning that substandard and falsified medicines have become a major global health threat. The headline estimate is the one worth repeating: up to one in ten medicines sold in low- and middle-income countries may be substandard or falsified.

The WHO pointed to a familiar set of drivers. Medicine shortages, high treatment costs, weak regulation, and the rapid growth of online sales have opened the door for criminal networks, and that door swings wider during emergencies and outbreaks. The report singled out lifestyle and weight-loss drugs as especially common counterfeiting targets, and it stressed that fake medicines do more than fail to treat. They worsen illness, fuel antimicrobial resistance, and erode trust in health systems.

India had a brutal month

If one country dominated the counterfeit headlines in May, it was India, and the stories were among the most serious of the year.

The most devastating broke late in the month. In Kota, Rajasthan, five pregnant and postpartum women died at a government medical college hospital after surgery. Laboratory tests on the oxytocin injections administered during treatment reportedly found zero active oxytocin content. Oxytocin is used to control bleeding after childbirth, so a counterfeit version is not merely ineffective. It is lethal in exactly the moment a patient needs it most. Around 16,000 of the injections had been supplied across the state, and authorities seized 3,501 and banned the suspect batch as the investigation widened.

Earlier in the month, Delhi Police Crime Branch busted a counterfeit drug racket worth close to 10 crore rupees, arresting four people who were allegedly manufacturing fake versions of expensive cancer and liver disease medicines and distributing them across multiple states.

A second Delhi operation exposed how deep the supply chain rot can run. An interstate syndicate was caught diverting genuine government-supply medicines out of Uttar Pradesh, stripping the original labels, and relabeling them for resale. The haul included counterfeit rabies vaccines, hepatitis B vaccines, insulin, human albumin, snake venom anti-serum, and cancer drugs. These are the medicines patients reach for in emergencies, which makes a fake one a quiet catastrophe.

Africa’s open-market problem stayed in focus

Nigeria’s Pharmacy Council reported sealing 1,550 pharmacies, patent medicine shops, and illegal outlets across Kano, Kaduna, and Nasarawa in a sweep that ran into mid-May. Kano alone accounted for 821 sealed premises. Regulators tied the crackdown to the country’s persistent burden of counterfeit and substandard antibiotics, antimalarials, and controlled substances sold through unregulated channels, and to the antimicrobial resistance that follows.

The trade dimension got attention too. In early May, the Office of the US Trade Representative flagged Kenya as a key destination and transit point in the global counterfeit goods network, pharmaceuticals included. The report described fakes shipped from manufacturing hubs through transit countries with weak enforcement, and a tactical shift worth noting: criminals are increasingly using small parcels sent through courier and postal services rather than large, easy-to-intercept shipments. The USTR cited an estimate that between 9 and 41 percent of medicines in low- and middle-income countries may be counterfeit.

The GLP-1 and pill-press fronts in the US

In the United States, two threads ran in parallel.

The Partnership for Safe Medicines published a May update on the weight-loss drug market, and the timing matters. The FDA approved two oral GLP-1 treatments in April, which the group expects will draw in patients who avoided injections and spawn a fresh wave of counterfeits. Fakes of semaglutide and tirzepatide products have already turned up in dozens of countries, sold through unregulated websites, gray-market peptide vendors, and med spas with thin oversight. The harm is no longer theoretical. The update points to hospitalizations, a liver transplant, and lawsuits tied to compounded and black-market versions.

On the pill-press front, lawmakers in Florida backed the PRESS Act in early May, aimed at restricting the machines used to stamp out counterfeit pills. The context is the overdose crisis: counterfeit pills laced with fentanyl and other synthetics continue to kill, often when a buyer believes they are taking something else entirely.

The through-line

Read across all of it and a clear shape emerges. Counterfeiters are not picking one lane. In a single month the fakes ranged from cheap antibiotics to oral cancer drugs, from maternal injectables to designer weight-loss pens. The selling has moved online and into small parcels that slip past traditional border checks. And the criminal networks behind it are organized enough to run for twenty years and generate hundreds of millions in revenue.

The common denominator is the gap between a patient and proof. When a package looks genuine, when a website looks legitimate, when a vial carries the right label, the patient has no way to know. Closing that gap is the entire point of brand protection and product authentication. Every story above is a story about a moment where a patient, a pharmacist, or a regulator could not tell the real from the fake fast enough.

That is the problem TrueMed exists to solve. The volume and variety on display this May are exactly why authentication cannot be left to patients, clinicians, or caregivers to know what to look for. The fakes are too convincing and the categories too broad for the human eye to be the last line of defense. It requires AI-assisted verification that confirms a product as genuine in seconds, from the artwork alone, with no special equipment and no change to the supply chain. That is how you close the gap between a patient and proof, and put a real answer in the hands of the people who need it most, wherever they are.

Sources

What March and April 2026 Showed Us

Two months of headlines, one consistent message: counterfeit pharmaceutical activity is accelerating across every region, every therapeutic category, and every distribution channel. From a landmark global investigation into fake cancer drugs infiltrating hospital supply chains to record-breaking fentanyl pill press sentences in the United States, March and April made clear that the threat is not confined to informal markets or developing economies. It is systemic.

United States: Sentencing, Seizures, and Supply Chain Fraud

Safe Chain Solutions: A Landmark Sentence

Charles and Patrick Boyd, co-owners of Safe Chain Solutions, received 20 and 18 years in federal prison respectively for counterfeit drug crimes and wire fraud. The Cambridge, Maryland-based distributor was at the center of a diversion ring that sold U.S. pharmacies over 85,000 counterfeit bottles of secondhand HIV medicine worth more than $250 million. This is one of the largest counterfeit drug cases in recent US history by both volume and dollar value.

Sources: PSM: Safe Chain sentence analysis  |  PSM: March 17, 2026 roundup

Counterfeit Oncology Drugs

Separately, 45-year-old Indian national Sanjay Kumar received a 43-month federal prison sentence for conspiring to sell counterfeit Keytruda to undercover law enforcement agents between 2018 and 2024. The fake versions he sold did not contain enough active ingredient to be effective.

Sources: PSM: March 10, 2026 — Fake cancer drug distributor sentenced

Fentanyl Pill Presses: Escalating Sentences

A Spokane, Washington man was sentenced to 20 years in prison for running a fentanyl pill press operation. A North Carolina man found with fentanyl pills and a pill press received a 35-year federal sentence for sex trafficking.

A South Carolina man was sentenced to 25 years in federal prison for manufacturing hundreds of thousands of counterfeit pills laced with fentanyl. Authorities seized 150,000 pills made to look like Roxicodone, 30 kilograms of fentanyl, pill stamps, and pill binders during the investigation.

Sources: PSM: March 10, 2026  |  PSM: April 27, 2026

Operation Spring Cleaning and Related Seizures

Florida authorities arrested 19 people as part of Operation Spring Cleaning, seizing 183.5 kilograms of counterfeit pills and over ten kilograms of other illicit drugs. Three California men were separately indicted on drug trafficking charges after the US Postal Service intercepted over 100 packages containing controlled substances, leading to the discovery of three pill presses and pill-making materials in a warehouse.

Sources: PSM: April 13, 2026

FDA Satellite Labs

The FDA highlighted its network of scientists at major mail facilities across the country who use advanced chemical analysis to detect and intercept dangerous, counterfeit, and illegal drugs before they reach consumers. The program is expanding to new locations including Honolulu to strengthen monitoring of Pacific-region imports.

Sources: PSM: April 20, 2026

United Kingdom: Weight-Loss Drug Fraud Deepens

The MHRA warned patients about counterfeit Mounjaro KwikPen injection pens dispensed by a private online clinic in Birmingham. Although testing confirmed the fakes contain tirzepatide, their manufacturing conditions are unknown, raising concerns about sterility and potential infection or allergic reactions.

The MHRA also raided two premises in England, disrupting a second facility suspected of manufacturing and distributing unlicensed retatrutide. Officers seized nearly 2,000 doses of unauthorized products, including manufacturing equipment, pharmaceutical ingredients, and packaging materials.

UK researchers found that cybercriminals are increasingly cloning legitimate online pharmacy websites and social media accounts to sell counterfeit weight-loss medications, often copying official regulator logos to appear trustworthy. The National Pharmacy Association suggested the government consider allowing pharmacies to use a dedicated domain such as pharmacy.uk to help patients identify regulated providers.

The MHRA also warned the public about counterfeit Viagra-style pills after working with eBay to remove 215 illegal online listings.

Sources: GOV.UK: Fake Mounjaro KwikPen warning  |  PSM: March 2, 2026 — MHRA raids  |  PSM: April 20, 2026 — Cloned pharmacy websites  |  PSM: April 13, 2026 — Counterfeit Viagra listings

Europe: Operation SHIELD VI Results Published

Results from Europol’s Operation SHIELD VI — which ran from April to November 2025 — were published in early March. The operation led to 3,354 prosecutions and the seizure of €33 million worth of counterfeit medicines and illegal supplements across 30 countries. It exposed how organized crime networks exploit growing demand for weight-loss drugs, performance enhancers, and recreational substances, including counterfeit semaglutide products and fake drugs containing dangerous synthetic substances like nitazenes.

The delayed publication of these results matters for brand protection teams. Operations of this scale take months to conclude, prosecute, and report. The counterfeit infrastructure that SHIELD VI dismantled was already well established by the time enforcement acted.

Sources: Europol: Operation SHIELD VI results  |  PSM: March 2, 2026

Asia: Philippines, India, and Vietnam

Philippines: Keytruda Seizure and China Smuggling

Filipino authorities arrested four suspects in Makati City after seizing approximately ₱102.5 million worth of counterfeit cancer drugs labeled as Keytruda during a sting operation. Separately, the Bureau of Customs in Manila seized over ₱53 million worth of counterfeit drugs shipped from China that were falsely declared as pet cages.

Sources: PSM: April 13, 2026 — Philippines seizures

India: Fake Mounjaro and Counterfeit Oncology Networks

Indian authorities seized ₹56 lakh of counterfeit Mounjaro injections and arrested two people. Eli Lilly confirmed it would assist in the investigation and support regulatory action.

Delhi Police also busted a large counterfeit medicine racket involving fake diabetes drugs and painkillers falsely branded under major pharmaceutical companies, arresting six people after uncovering a factory, storage sites, and a fraud network.

Sources: PSM: April 20, 2026 — India Mounjaro seizure  |  PSM: April 13, 2026 — Delhi Police bust

Vietnam

Police in Vietnam dismantled a counterfeit medicine ring that produced and sold fake traditional drugs mixed with paracetamol, arresting three suspects in the operation.

Sources: PSM: April 20, 2026 — Vietnam ring dismantled

Pakistan and Saudi Arabia: Regulatory Alerts

Pakistan’s Drug Regulatory Authority issued an emergency alert after six commonly used medicines in Punjab were found to be counterfeit or substandard, warning the public to stop using them immediately due to serious health risks.

Saudi Arabia’s Ministry of Health detained multiple gym trainers for promoting and selling unregistered peptides and hormonal drugs. Monitoring of social media by the Saudi Food and Drug Authority led investigators to a warehouse storing the drugs, including retatrutide. Officials raised concerns about improper storage conditions and urged the public to obtain drugs only through legitimate supply chains.

Sources: PSM: April 27, 2026 — Pakistan alert  |  PSM: April 6, 2026 — Saudi Arabia gym trainers

Canada: Peptide Warning

Health Canada warned the public against using unauthorized injectable peptide drugs sold online, noting they have not been assessed for safety, quality, or effectiveness. The agency advised Canadians to obtain prescription medications only from licensed pharmacies, as many products available through unregulated online channels may be contaminated, mislabeled, or dangerous.

Sources: PSM: April 20, 2026 — Health Canada peptide warning

Consumer Behavior: New Research Confirms the Scale

A Michigan State University study published in late April added important context to enforcement data. Researchers surveying nearly 5,000 participants across eight countries found that one in five consumers has been deceived into buying counterfeit medicines, while one in four has knowingly purchased them.

The study also found that social norms strongly influence purchase behavior — consumers who believed their close family and friends accepted counterfeit purchases were significantly more likely to buy them, both intentionally and unintentionally.

For brand protection teams, this matters. Enforcement removes product from circulation. It does not change the conditions that drive demand toward unverified sources.

Sources: MSU Today: 1 in 5 consumers deceived into buying fake meds

Where This Leaves Brand Protection Teams

March and April reinforced two things.

First, counterfeit activity is now firmly embedded in premium therapeutic categories — oncology, GLP-1s, injectable aesthetics. These are not low-margin targets. They are high-visibility, high-demand products with global patient populations and deeply asymmetric pricing. The combination creates sustained criminal incentive that enforcement alone cannot eliminate.

Second, the distribution channels have diversified beyond seizure capacity. Cloned pharmacy websites, social media resale, master carton smuggling, and domestic compounding fraud are all operating in parallel. Each channel requires a different detection approach.

Brands in high-risk categories cannot wait for enforcement to surface the threat. The question is how quickly exposure can be identified and validated before harm scales.

Primary sources: ICIJ, Partnership for Safe Medicines, Europol, MHRA, GOV.UK, NAFDAC, US DOJ, FDA, CBP, TheDiggerNews, Yucatan Times, MSU Today

Counterfeiting is no longer a series of isolated incidents. It is organized, adaptive, and often global. As fake products become harder to spot and faster to replicate, brand protection teams need better ways to connect the dots between what they are seeing in the field. This is where counterfeit strain analysis comes in.

At its core, strain analysis applies AI and machine learning techniques to group counterfeit products that likely share a common origin. Instead of treating each fake as a one-off problem, strain analysis looks for patterns across artworks to identify groups of counterfeits that may be coming from the same source or network.

From Clustering to Strain Analysis

In data science, clustering is a machine learning technique used to group similar objects or data points together based on shared characteristics or patterns. Counterfeit strain analysis builds on this idea by applying clustering specifically to counterfeit products. The goal is not just to say that two items look alike, but to assess whether they are likely connected through shared production methods, suppliers, or criminal operations.

This shift in perspective changes how brands respond to counterfeiting. Instead of playing whack a mole with individual takedowns, strain analysis helps teams understand how counterfeit operations are structured and how they evolve over time.

The Real World Benefits of Counterfeit Strain Analysis

When strain analysis is applied consistently, it unlocks a set of strategic benefits that go well beyond basic detection.

Revealing organized operations across markets

Finding the same or highly similar counterfeit artwork in different regions often signals larger or even international criminal organizations. Strain analysis makes these patterns visible, helping teams recognize when they are dealing with coordinated networks rather than isolated bad actors.

Understanding regional and global counterfeit activity

By grouping counterfeits into distinct strains, brands can better understand how counterfeit activity differs by geography. This allows teams to see where certain strains are spreading, which regions are being targeted, and how tactics differ from one market to another.

Identifying new variants and linking to past investigations

Counterfeiters frequently change small details in their packaging or products to avoid detection. Strain analysis helps identify when a counterfeit represents a new variant of an existing strain and whether it can be linked back to previous cases. This continuity is critical for building stronger investigative narratives over time.

Tracking how counterfeiters evolve their methods

Bad actors often upgrade their artwork or packaging, but they tend to reuse or conserve certain elements from earlier versions. Strain analysis can surface these shared elements across different counterfeit groups, revealing how operations evolve while still leaving behind recognizable fingerprints.

Connecting counterfeit activity across different products

In many cases, the same counterfeit operation is responsible for fakes across multiple products or brands. Strain analysis helps identify these cross-product patterns, giving brands a clearer view into how individual counterfeiters operate and diversify their efforts.

Informing packaging and product development

Strain analysis can also feed back into prevention. By identifying which packaging components or security features are most frequently exploited or mimicked in the field, brands can make more informed decisions about where their current protections are failing and where future improvements should focus.

Moving From Incidents to Intelligence

The biggest shift strain analysis enables is moving from incident response to intelligence driven brand protection. Instead of simply reacting to counterfeit finds, teams can begin to map counterfeit ecosystems, prioritize the most impactful threats, and align enforcement, legal, and packaging strategies around real patterns in the market.

Over time, as more data is collected and more counterfeit samples are analyzed, strain analysis becomes more powerful. The insights compound. Patterns become clearer. And brand protection efforts become more proactive, targeted, and effective.

Why This Matters Now

Counterfeiting is becoming more sophisticated, not less. As counterfeiters adopt better printing, manufacturing, and distribution tactics, brands need equally sophisticated tools to keep up. Counterfeit strain analysis offers a way to see beyond individual fakes and start understanding the operations behind them.

For brand protection teams, that shift in visibility can be the difference between chasing symptoms and disrupting the source.

What February 2026 Showed Us

If February proved anything, it is this: counterfeit pharmaceutical activity is not isolated, not regional, and not slowing down. From large-scale online pharmacy takedowns to fake GLP-1 injectables circulating in major markets, enforcement activity spanned nearly every continent. What we are seeing is not opportunistic crime. It is structured, repeatable, and increasingly sophisticated.

Here is what stood out this month and why it matters for brand protection teams responsible for protecting both revenue and patient safety.

Illegal Online Pharmacies: A Global Infrastructure Problem

The DEA’s Operation Meltdown resulted in the seizure of hundreds of illegal online pharmacy domains connected to a transnational criminal network. These were not small operations. They were structured, professional, and designed to look legitimate to consumers searching for convenience or lower prices.

Investigations continue to show how these sites mimic real pharmacies, use payment processing tools that appear compliant, and exploit supply shortages to drive urgency. The infrastructure behind them is agile, which means domains can disappear and reappear quickly under new names.

Links:

https://www.dea.gov/press-releases/2026/02/04/dea-operation-meltdown-shuts-down-hundreds-illegal-online-pharmacies

https://www.pharmacy.biz/india-illegal-online-pharmacies

For brands, this reinforces a hard truth. Shutting down websites is necessary, but preventing counterfeit product from being trusted in the first place is what ultimately reduces harm.

Europe: Coordinated Enforcement Is Expanding

Europol’s Operation SHIELD VI led to hundreds of prosecutions and millions of euros in seized illicit medicines. Austrian customs and other authorities intercepted large volumes of counterfeit pills moving across borders, demonstrating growing cross-agency coordination.

The operation targeted not only finished counterfeit medicines but also trafficking networks, doping substances, and organized pharmaceutical crime rings operating across EU member states.

Links:

https://www.europol.europa.eu/media-press/newsroom/news/3354-individuals-prosecuted-in-europol-coordinated-hit-against-pharmaceutical-crime-networks

https://www.visahq.com/news/2026-02-25/at/austrian-customs-help-seize-31-million-counterfeit-pills-in-eu-wide-shield-vi-operation

Encouraging as these actions are, most seizures happen after product has already entered circulation. Earlier identification remains the missing link.

GLP-1 and Weight-Loss Drugs: Demand Driving Risk

Regulators in the UK issued warnings about fake Mounjaro pens, while investigations tied to counterfeit Ozempic and similar injectables continue. Media outlets are now publishing consumer advice on how to identify scams, which shows that the issue has moved into mainstream awareness.

GLP-1 therapies sit at the intersection of high price, high demand, and limited supply. That combination creates ideal conditions for counterfeiters. Social media resale channels and informal online marketplaces are amplifying the risk.

Links:

https://www.gov.uk/government/news/fake-mounjaro-tirzepatide-kwikpen-15mg-pre-filled-pens

https://www.msn.com/en-gb/news/uknews/london-police-hunt-woman-over-32-000-haul-of-fake-weight-loss-drugs-ozempic-and-mounjaro/ar-AA1LxrW7

https://www.thesun.co.uk/health/38334494/spot-fat-jab-scam-tips-black-market

For brand owners in this category, proactive monitoring and product-level verification are foundational to protecting patients and preserving trust.

North America: Counterfeit Pills and Hidden Ingredients

In the United States, authorities reported large counterfeit pill seizures tied to regional drug busts. These cases often involve pills pressed to resemble known brands but containing entirely different substances.

At the same time, regulatory alerts continue to surface around dietary supplements adulterated with undisclosed prescription ingredients. Consumers may believe they are purchasing safe over-the-counter products when in fact they are exposed to potent pharmaceuticals.

Links:

https://fox59.com/news/indynews/3-arrested-688000-in-counterfeit-pills-seized-in-tippecanoe-county-drug-bust

https://www.msn.com/en-us/health/nutrition/counterfeit-dietary-supplement-tainted-with-drug-used-to-treat-ed-warns-fda/ar-AA1WpCCc

https://www.insauga.com/fake-ozempic-like-drugs-flooding-canada-pose-a-serious-danger-feds-report

Counterfeit risk today is as much about composition as it is about packaging. Wrong ingredients and incorrect dosing create direct patient safety threats.

India: Manufacturing and Distribution Networks Exposed

Multiple enforcement actions across India uncovered counterfeit factories, fake packaging operations, and interstate supply chains distributing lookalike medicines. Reports described seized tablets, packaging materials, and coordinated logistics moving product across state lines.

These were not isolated incidents. They reflect repeatable production models capable of scaling quickly when demand exists for a targeted product.

Links:

https://pioneeredge.in/fake-medicines-racket-police-arrests-another-accused

https://www.hindustantimes.com/india-news/massive-counterfeit-himalaya-drugs-gang-busted-in-ghaziabad-police-reveal-two-state-modus-operandi-101770605682706.html

https://dailypioneer.com/news/police-bust-second-fake-medicine-factory-in-bihar-total-9-arrested

https://indianexpress.com/article/cities/delhi/delhi-police-antf-fake-medicine-factory-gaya-bihar-tramadol-seizure-arun-arrest-10532587

https://medicaldialogues.in/news/industry/pharma/fake-telma-am-racket-busted-in-thane-two-pharma-distributors-arrested-165020

When counterfeiters can source packaging, replicate labeling, and distribute at scale, visual inspection alone becomes unreliable.

Africa: Sustained Pressure on High-Risk Medicines

In Nigeria, NAFDAC dismantled major drug warehouses containing large volumes of fake medicines. Public commentary continues to call for stronger enforcement across the region, particularly in high-risk categories such as oncology.

In Kenya, editorials stressed the urgency of eliminating counterfeit cancer drugs. In critical therapies, counterfeit exposure can directly impact survival outcomes.

Links:

https://saharareporters.com/2026/02/10/nafdac-dismantles-lagos-drug-warehouses-seizes-fake-medicines-worth-over-n10billion

Senator Natasha Hails NAFDAC’s Crackdown On Fake Drugs

https://www.standardmedia.co.ke/editorial/article/2001541007/rid-kenya-and-africa-of-counterfeit-cancer-drugs

For global brands operating in these markets, monitoring cannot be limited to primary distribution channels.

Where This Leaves Brand Protection Teams

The common thread across these headlines is scale and persistence. Counterfeiters are operating across channels, across borders, and across therapeutic categories.

Enforcement will continue, and cooperation between agencies is improving. Long-term deterrence depends on earlier detection, faster validation, and evidence that stands up in legal and regulatory environments.

For brands, the question is no longer whether counterfeit exposure exists. The question is how quickly it can be identified and proven before it spreads.

January opened the year with a sharp reminder that counterfeit and substandard medicines remain a global public health threat. From fake GLP-1 weight loss drugs and counterfeit Botox to fentanyl-laced pills and illegal manufacturing operations, regulators across North America, Europe, Asia, and Australia issued urgent warnings and carried out major enforcement actions. Here is a snapshot of the most notable developments.

Black Market Medications and Growing Consumer Risk

Investigations highlighted the scale of the black market for prescription medications, warning that millions of consumers are being exposed to fake and potentially dangerous drugs through online channels and informal supply chains. These products often appear authentic but may contain incorrect dosages, harmful ingredients, or no active ingredient at all.
Source:
https://www.yahoo.com/news/articles/black-market-medications-warning-millions-000002144.html

Potent Counterfeit Drugs Trigger Local Drug Alerts

Health authorities in Winnipeg issued a drug alert after potent counterfeit products were identified in circulation, raising concerns about overdose risk and unpredictable strength. Public health officials urged people to avoid unregulated sources and seek testing or medical support if exposed.
Source:
https://ca.news.yahoo.com/drug-alert-issued-winnipeg-potent-152530589.html

Med Spa Crackdowns Reveal Illegal Procedures and Fake Products

A crackdown on med spas in New York uncovered illegal procedures and the use of unauthorized and potentially counterfeit injectables. Officials warned consumers that cosmetic treatments performed with unapproved products can lead to serious injuries and long term health complications.
Source:
https://dailyvoice.com/new-york/rye/med-spa-crackdown-finds-illegal-procedures-serious-injuries-ny-warns-consumers/

Fake Viagra Remains the UK’s Most Seized Counterfeit Drug

UK authorities reported that counterfeit Viagra continues to top seizure lists, with criminal networks flooding the market through online pharmacies and social media. Consumers were advised to verify sources and avoid purchasing prescription drugs outside legitimate pharmacy channels.
Source:
https://www.msn.com/en-gb/news/uknews/fake-viagra-is-the-uk-s-most-seized-counterfeit-drug-heres-how-to-avoid-it/ar-AA1K0Dye

India Confronts a Growing Fake and Substandard Medicines Crisis

Reports from India underscored a widening crisis involving fake and substandard medicines entering local supply chains. Regulators warned that weak oversight and fragmented distribution networks make patients especially vulnerable to falsified products.
Source:
https://english.mathrubhumi.com/news/kerala/india-fake-substandard-medicines-crisis-iwadffuz

Counterfeit Anti Epilepsy Drugs Seized in Telangana

Authorities seized fake versions of Levipil 500 tablets posing as a legitimate Sun Pharma product. The incident highlights the persistent risk of counterfeit branded medicines infiltrating pharmacies and wholesalers.
Source:
https://medicaldialogues.in/news/industry/pharma/fake-levipil-500-tablets-posing-as-sun-pharma-product-seized-in-telangana-162709

Fake Medicine Factory Shut Down After Police Raid

Police shut down an illegal manufacturing unit producing counterfeit medicines, reinforcing concerns about organized operations that manufacture fake drugs at scale before distributing them through informal channels.
Source:
https://kashmirlife.net/fake-medicine-factory-sealed-after-police-raid-421710/

Crackdown on Counterfeit Cough Syrup Manufacturing

Law enforcement exposed an illegal manufacturing unit producing counterfeit cough syrup, part of a broader pattern of falsified over the counter products entering local markets without quality or safety controls.
Source:
https://www.devdiscourse.com/article/law-order/3776527-crackdown-on-cough-syrup-counterfeit-illegal-manufacturing-unit-exposed

Senators Question Regulators Over Online Counterfeit Sales

Philippine senators grilled regulators over the continued online sale of counterfeit and unregistered health products, pointing to gaps in enforcement and digital marketplace oversight.
Source:
https://mb.com.ph/2026/01/27/senators-grill-fda-over-online-sale-of-counterfeit-unregistered-health-products

Health Canada Flags Rising GLP-1 Counterfeit Risk

Health Canada warned of increasing counterfeit risk tied to GLP-1 weight loss drugs, as demand continues to outpace legitimate supply. Patients were cautioned about fake Ozempic and similar products circulating online.
Source:
https://www.benefitsandpensionsmonitor.com/benefits/pharma/health-canada-flags-rising-glp-1-counterfeit-risk-for-canadian-patients/393002

Counterfeit Ozempic Detected in Canada

Canadian authorities confirmed counterfeit Ozempic in the market, raising alarm over the safety of products obtained outside regulated pharmacy channels. Officials emphasized the importance of secure sourcing and verification.
Source:
https://www.cbc.ca/news/health/ozempic-health-canada-counterfeit-9.7054857

Warnings Issued Against Unregistered Medicines and Health Products

Health agencies in the Philippines issued public warnings against unregistered medicines and health products being sold through informal and online channels, many of which are suspected counterfeits.
Source:
https://newsinfo.inquirer.net/2172743/doh-fda-issue-warning-against-unregistered-meds-health-products

Counterfeit Botox Identified in Australia

Australia’s regulator detected counterfeit Botox products in circulation and warned clinics and consumers to be alert for unapproved injectables that can pose serious health risks.
Source:
https://www.abc.net.au/news/2026-01-28/counterfeit-botox-items-detected-by-tga-in-australia/106278732

Fake Weight Loss Injections and Pills Seized in UK Raids

UK authorities seized large quantities of fake weight loss injections and pills from black market sellers, reflecting the growing counterfeit risk tied to lifestyle and aesthetic medicines.
Source:
https://www.thesun.co.uk/health/38036436/fake-meds-seized-black-market-fat-jabs-pills/

FDA Seizes Millions in Fake Medicines

Authorities reported major seizures of counterfeit medicines valued in the millions, demonstrating the industrial scale of fake drug operations and the ongoing challenge facing regulators.
Source:
https://www.bworldonline.com/the-nation/2026/01/27/726865/fda-seizes-p56-8-m-fake-medicines/?amp

Fake Medicines Seized at Pharmacy Inspection

Inspections at a pharmacy uncovered fake medicines, reinforcing the need for stronger supply chain controls even at the point of sale.
Source:
https://pragnews.com/en/fake-medicines-seized-in-inspection-at-nagaon-pharmacy

Fentanyl Contaminated Counterfeit Drugs Trigger Public Warning

Authorities in Kelowna warned the public about counterfeit drugs containing fentanyl, highlighting the deadly risk when falsified medicines intersect with the illicit drug supply.
Source:
https://lakecountrycalendar.com/2026/01/29/warning-issued-for-counterfeit-drugs-containing-fentanyl-in-kelowna/

Counterfeit Trends Brand Protection Teams Should Be Watching in 2026

Counterfeit medicines did not slow down in 2025. They evolved. Law enforcement continues to make record seizures, illegal online pharmacies keep multiplying, and the surge in GLP-1 demand has created one of the most attractive targets counterfeiters have ever had (Interpol Operation Pangea). For brand protection teams, this means 2026 requires faster decision making, stronger field visibility, and practical tools that help protect both brands and patients.

————————————————————

  1. The GLP-1 Market Is Still the Biggest Counterfeit Target

————————————————————

GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reshaped healthcare conversations in 2024 and 2025. At the same time, they also became a major focus for counterfeiters and illegal distributors (FDA Warning on Counterfeit Semaglutide). Regulators and investigators continue warning about real patient safety risks, including harmful outcomes when non legitimate versions are used (BBC coverage).

With oral GLP-1 pills entering the market, the challenge expands further. Tablets are easier to move through shipping channels, easier to mix in bulk, and many consumers view them as less risky. This only increases the need for monitoring and fast identification.

What this means for brand protection:

  • GLP-1 products deserve a dedicated risk strategy
  • Fake pill packaging is likely to appear rapidly
  • Monitoring must include social platforms, wellness storefronts, and nontraditional online pharmacy models

————————————————————

  1. Counterfeit Networks Are Growing Through Digital Channels

————————————————————

Counterfeit medicines are not only moving through back channels anymore. Many are organized, technology driven operations. Investigations continue to uncover large cross border networks and illegal online pharmacy ecosystems (U.S. DOJ Enforcement Reports), along with major global enforcement campaigns targeting distribution at scale (Interpol).

For brand protection teams, online visibility is now essential. Listings return quickly after takedowns. Influencers, search platforms, and social commerce all play a role in how counterfeit products reach consumers.

————————————————————

  1. Serialization Remains Important, But It Cannot Be the Only Defense

————————————————————

Serialization and QR programs have been important advances. They help improve transparency and supply chain control. However, visible codes can still be photographed, duplicated, or reapplied. Industry experts have already highlighted how counterfeiters are adapting to these systems (Industry Analysis).

The takeaway is straightforward. Serialization remains critical, but it should be viewed as one layer in a broader protection strategy.

————————————————————

  1. AI Is MovingFromConcept to Daily Brand Protection Practice

————————————————————

The biggest change for 2026 is the role of artificial intelligence. AI is no longer something theoretical in brand protection conversations. It is becoming a practical, everyday part of how organizations identify risk, authenticate products, and respond to emerging threats.

AI powered authentication can analyze subtle details in packaging and product design that are extremely difficult for counterfeiters to replicate. This can be done through smartphone images, which means it can work on products that are already in the field (TrueMed AI Authentication).

AI is also helping teams:

  • Identify earlier warning signs of new risks
  • Understand where problems are building geographically
  • Connect digital activity with real world outcomes
  • Respond faster when a threat appears

It also helps during enforcement. AI allows teams to prioritize real threats, support investigations, and provide stronger evidence for regulators and law enforcement (McKinsey AI Risk Insights).

TrueMed supports this direction by enabling AI authentication without requiring packaging redesigns or manufacturing changes. It strengthens intelligence with every scan and helps protect products that are already in circulation (TrueMed).

————————————————————

  1. What Experts and Regulators Continue to Emphasize

————————————————————

In almost every major discussion about counterfeit medicines in 2025, whether from regulators, healthcare professionals, brand protection leaders, or law enforcement, the same messages continued to appear. Counterfeiting is no longer a fringe activity run by a few small operations. It is organized, financially driven, technology enabled, and increasingly difficult for patients and even healthcare professionals to spot without help. Regulators continue to stress that misinformation, misleading online promotions, and non legitimate distribution channels are creating real patient risk (FDA Commentary).

Another consistent theme is responsibility. Regulators are placing clearer expectations on manufacturers and brand owners to actively protect their products. It is no longer enough to simply comply with basic serialization rules and assume the risk ends there. Agencies and legal analysts are pointing out that best practice now includes stronger authentication programs, better consumer education, and active monitoring of online and offline markets. Organizations that take these steps are seeing faster detection of problems, fewer incidents, and stronger trust with healthcare systems and consumers.

Healthcare professionals are also speaking more directly about the issue. Physicians and pharmacists are reporting growing concern about patient confidence, particularly around high demand therapies such as GLP 1 medicines. Many clinicians are asking manufacturers to provide clearer ways to verify products, easier reporting paths, and better communication tools that help educate patients about risk without causing unnecessary fear. When authentication is simple and practical, it builds confidence rather than anxiety, which is exactly what the market needs right now.

Law enforcement and international agencies continue to emphasize collaboration. Counterfeit operations rarely exist within one country anymore. They move through multiple regions, online networks, and complex distribution chains. Brand owners who share intelligence, participate in coordinated enforcement efforts, and build relationships with regulators and investigative bodies tend to close cases faster and reduce repeat activity. The message is clear. This problem requires coordination, not isolated efforts.

All of this reinforces a simple conclusion. Counterfeiting is not only a manufacturing or packaging problem. It is a patient safety issue, a brand trust issue, and a regulatory expectation. The brands that do best are the ones that take the topic seriously, invest in meaningful authentication capabilities, and communicate clearly with the people who rely on their products.

December’s headlines delivered a familiar pattern with a few unsettling twists: more fake medicines moving through everyday channels, more “too-good-to-be-true” health products online, and more counterfeit activity clustering around high-demand categories like GLP-1 weight-loss drugs, sexual performance meds, and common cold/cough and chronic-disease therapies.

1) Public health warnings: “Stop buying meds online from unknown sellers”

Health authorities in the Philippines again warned consumers about counterfeit medicines and vaccines, with a specific callout to online and unauthorized sellers and common red flags like label errors, unfamiliar packaging, and missing batch, lot, and expiration information.

Why it matters: these alerts are basically saying the quiet part out loud: counterfeits are no longer “rare edge cases.” They are expected enough that public guidance now reads like a standing safety protocol. Philstar.com

 

2) Counterfeit lifestyle and high-demand meds: Viagra/Cialis seized in Canada

Canadian authorities issued an updated public advisory after fake Viagra and Cialis were seized from a convenience store in Toronto.
Link:

The bigger signal: counterfeiters keep choosing categories where demand is high, stigma reduces questions, and people self-source outside traditional care pathways.

 

3) GLP-1s and “weight-loss everything”: the counterfeit ecosystem expands

This month also reinforced the reality that GLP-1 demand is creating a wider counterfeit and gray-market orbit, including fake products and questionable ingredients marketed to consumers chasing availability or price.
Link:

And on the enforcement side, FDA-related reporting flagged counterfeit Ozempic (semaglutide) seizures, underscoring how quickly fakes show up once a product becomes culturally and commercially dominant.

 

4) “Not even a clinic”: counterfeit aesthetics and illegal injectables (Texas)

In the U.S., a case out of Sugar Land spotlighted something consumers do not always consider: counterfeit risk is not limited to pills. Authorities charged a woman for allegedly practicing medicine without a license, including injecting a patient with counterfeit filler.

Takeaway: counterfeit harm is increasingly “service-enabled.” It can be packaged as a cosmetic appointment, a wellness visit, or a pop-up provider.

 

5) South Asia: counterfeit “flooding,” staffing gaps, and stepped-up inspections

Several December stories across India point to a blend of pressure and progress: more inspections and crackdowns, but also real constraints like unfilled inspector roles and repeated incidents across product types.

 

6) India alert and ripple effects: dozens of suspect products flagged

A major thread this month involved Puducherry, India, where authorities identified and escalated an alert tied to multiple suspected counterfeit/spurious medicines detected in-market, pushing awareness outward to regulators and the broader ecosystem.

Why it matters for brands: this is the modern counterfeit pattern. One seizure is not just one incident. It is a signal flare pointing to distribution pathways, repeatable packaging tactics, and a network that likely spans multiple states, sellers, and product categories. 

7) Nigeria: police seal a fake drug factory

In Lagos, police reportedly sealed a fake drug factory, another reminder that counterfeit operations can be industrial, not improvised.
Link:

 

8) “Seized,” “busted,” “sentenced”: enforcement actions with real numbers behind them

A few December items are worth grouping together because they show something important: enforcement is happening, but it is often reactive, and it usually arrives after products are already in circulation.

What December adds up to

If you read these stories back-to-back, a few themes jump out:

  1. Counterfeits are following demand curves. GLP-1s, lifestyle meds, and frequently used therapies are magnets. coloradonewsline.com

  2. The “point of sale” is everywhere now. Convenience stores, social platforms, informal sellers, pop-up providers, and gray-market wholesalers all show up in the same monthly cycle. Newswire

  3. Enforcement is real, but it is not a shield by itself. Most crackdowns are after the fact, and staffing gaps make sustained pressure difficult. The Times of India

 

As I reflect on 2025, I feel a deep sense of pride, humility, and renewed commitment. This year reminded all of us at TrueMed why our mission matters. Around the world, patients continued to face an unprecedented rise in counterfeit medicines, and the need for rapid, reliable, and accessible authentication reached a new level of urgency.

Rising to a Global Counterfeit Crisis

2025 brought extraordinary clarity to the scale and sophistication of counterfeit drug operations. Month after month, our Counterfeit Drug News Roundups documented a pattern that spanned continents and therapeutic areas.

Large seizures of falsified cancer drugs, antibiotics, and allergy medications took place in India and Southeast Asia early in the year. As demand for certain products intensified, global markets saw increasing volumes of fake GLP-1 treatments, unsafe injectables, falsified Botox in Australia, and oncology medicines containing little or no active ingredients. These were not distant stories. They were reminders that every incident represents patients whose health was placed in jeopardy.

Advancing TrueMed’s Mission and Expanding Our Footprint

While counterfeit activity surged, 2025 was also a year when TrueMed’s momentum accelerated across the pharmaceutical industry. More companies adopted our AI authentication platform than ever before, expanding its use into additional product lines, new geographies, and new investigative teams.

The most recent use-case example comes from Alliance Pharmaceuticals Ltd., which demonstrated how new technology can deliver significant impact in the field, reducing observed counterfeits by 90% through dramatically improved speed and accuracy. TrueMed provided technology is set to transform field operations with its comprehensive capabilities, offering far more than a simple yes-or-no verification. The data, much more than yes or no data, collected in the field will become an invaluable resource, providing powerful insights and driving future activities in the field as well as in the packaging development.

This collective movement reflects a broader shift. Companies are no longer willing to rely solely on legacy security features that are slow to take in use and compromised quickly, or fully manual inspection which industry has been driving for years. They are embracing technology that can narrow hundreds of suspect units to a few meaningful targets in hours instead of weeks or months. They are investing in visibility, speed, and scalable defenses that match the pace of today’s counterfeiters.

Our work with top pharmaceutical partners reinforced this transition. A top ten pharma company selected TrueMed for advanced counterfeit investigations, underscoring how essential AI has become in protecting products already in market.

These advancements were not just announcements. They translated into measurable impact. Our case studies highlighted real-world results, from immediate clarity during investigations to dramatic reductions in counterfeit incidents after clients fully integrated TrueMed into their workflows.

Growth, Expansion, and New Capabilities

TrueMed continued to grow as a company throughout 2025. We expanded our physical presence, strengthened engineering and product teams, and increased our capacity to support deployments around the world. We welcomed new customers across diverse therapeutic categories, each bringing unique challenges and reinforcing the universal need for a modern, frictionless approach to product authentication.

This expansion has allowed us to support more product launches, broaden our global field coverage, and help companies protect existing inventory already distributed across multiple regions. Every engagement reaffirmed a core truth. Patients depend on the decisions we make and the technologies we deliver.

Trends That Defined 2025

Counterfeits grew significantly more sophisticated. Replicated batch numbers, cloned holograms, copied stickers, even compromised RFID tags, and increasingly accurate packaging became common. Traditional layered security models struggled to keep up.

Demand driven black markets continued to expand. GLP-1 treatments experienced unprecedented popularity, and with that popularity came a wave of fakes seeking to exploit vulnerable patients.

The counterfeit threat became more global and more coordinated. Incidents spread across Europe, Asia, the Middle East, Africa, and the Americas. Each region experienced unique patterns, but all required faster authentication and improved investigative workflows.

Pharmaceutical companies shifted toward proactive protection. Anti-counterfeit measures are now being positioned as a core element of patient safety, operational integrity, and regulatory readiness. This shift has been a major driver behind the rapid adoption of TrueMed.

Hope, Progress, and a Renewed Commitment

Despite the challenges, I am optimistic. The progress we saw in 2025 proved that innovation can move faster than the threat when it is backed by purpose, clarity and focus. Companies using TrueMed reduced risk, improved detection accuracy, and strengthened their ability to respond quickly.

The path forward requires vigilance and continual evolution. Counterfeiters will again adjust. Our responsibility is to stay ahead of those adjustments, expand our capabilities, and help every partner strengthen their protection strategy without disrupting manufacturing, packaging, or distribution.

Gratitude for the Team, Partners, Customers, and Patients

I want to express my sincere appreciation to the TrueMed team for their talent, ingenuity, and commitment to our mission. I am equally grateful to the customers and partners who trusted us to support their efforts to safeguard medicines already in the field.

Most importantly, I am grateful to the patients whose safety drives every innovation we introduce. You are the reason we push forward and the reason this work matters.

As we move into 2026, we carry the lessons of this year with focus and determination. TrueMed will continue to lead with purpose, innovation, and a clear commitment to restoring confidence in the authenticity of medicines around the world.

Let's Talk

Speak with Experts Ready to Back your Fight

Our team of experienced experts specializing in brand value and product protection solutions is at your service. They will work closely with you to craft a tailored solution that addresses your unique requirements. We firmly believe in empowering you to make the decision that best suits your business. Your satisfaction and confidence in our partnership are paramount, and we can’t wait to help you solve through challenges.